A new study presents a customised treatment strategy using antisense oligonucleotides (ASOs) to target EGFR mutations in ...

For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...

November is Lung Cancer Awareness Month, and early detection is in the air. According to the Centers for Disease Control, ...

According to Cancer Research UK, just 10% of patients survive for ... These are known as ALK-positive and EGFR-positive lung ...

By Dr. Sushama R. Chaphalkar, PhD. By combining advanced gene editing techniques, scientists identified key mutations that ...

Lung cancer is the top cause of cancer-related deaths globally, more prevalent in men, and ranks third among women. Both ...

In a study led by researchers at the NUS Yong Loo Lin School of Medicine, extracellular vesicles loaded with customizable ...

ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced its financial results for the third quarter of 2024, alongside ...

Researchers have used microcellular "drones" to deliver antisense oligonucleotide therapeutics to lung cancer cells.

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

Sunvozertinib has shown promising results in patients with non–small cell lung cancer with an EGFR exon 20 insertion mutation ...